Tags

Type your tag names separated by a space and hit enter

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
J Med Virol 2006; 78(4):440-5JM

Abstract

In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and A H3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-gamma levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0 +/- 229.8 pg/ml to a 30-day level of 390.7 +/- 606.3 pg/ml (P < 0.05), with concentrations significantly higher (P < 0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4+ cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.

Authors+Show Affiliations

Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

16482542

Citation

Tanzi, Elisabetta, et al. "Immunogenicity and Effect of a Virosomal Influenza Vaccine On Viral Replication and T-cell Activation in HIV-infected Children Receiving Highly Active Antiretroviral Therapy." Journal of Medical Virology, vol. 78, no. 4, 2006, pp. 440-5.
Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol. 2006;78(4):440-5.
Tanzi, E., Esposito, S., Bojanin, J., Amendola, A., Trabattoni, D., Pariani, E., ... Principi, N. (2006). Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. Journal of Medical Virology, 78(4), pp. 440-5.
Tanzi E, et al. Immunogenicity and Effect of a Virosomal Influenza Vaccine On Viral Replication and T-cell Activation in HIV-infected Children Receiving Highly Active Antiretroviral Therapy. J Med Virol. 2006;78(4):440-5. PubMed PMID: 16482542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. AU - Tanzi,Elisabetta, AU - Esposito,Susanna, AU - Bojanin,Jelena, AU - Amendola,Antonella, AU - Trabattoni,Daria, AU - Pariani,Elena, AU - Pinzani,Raffaella, AU - Zanetti,Alessandro, AU - Principi,Nicola, PY - 2006/2/17/pubmed PY - 2006/5/27/medline PY - 2006/2/17/entrez SP - 440 EP - 5 JF - Journal of medical virology JO - J. Med. Virol. VL - 78 IS - 4 N2 - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and A H3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-gamma levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0 +/- 229.8 pg/ml to a 30-day level of 390.7 +/- 606.3 pg/ml (P < 0.05), with concentrations significantly higher (P < 0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4+ cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients. SN - 0146-6615 UR - https://www.unboundmedicine.com/medline/citation/16482542/Immunogenicity_and_effect_of_a_virosomal_influenza_vaccine_on_viral_replication_and_T_cell_activation_in_HIV_infected_children_receiving_highly_active_antiretroviral_therapy_ L2 - https://doi.org/10.1002/jmv.20559 DB - PRIME DP - Unbound Medicine ER -